Sandoz associates join Novartis Community Partnership Day 2014

Holzkirchen, May 15, 2015 – More than 19,000 Novartis associates worldwide volunteer for local causes on Community Partnership Day

Novartis associates across 55 countries engaged in local volunteer efforts to support their communities in celebration of the company’s annual Community Partnership Day (CPD).

May 8th of this year marked the 18th Community Partnership Day, commemorating the 1996 creation of Novartis as a global leader in healthcare.

There is strong participation from all Novartis divisions in 2014, including Sandoz. Here we feature some …

/by

Sandoz launches generic version of key anti-depressant Cipralex® in several European countries

Holzkirchen, June 4, 2014 – Sandoz, the generic pharmaceuticals division of Novartis, today announced the launch in several European countries of generic escitalopram, an affordable and high-quality version of reference product Cipralex®.

The Sandoz product, which is available in all strengths approved for the reference product (5mg, 10mg, 15mg and 20mg), was launched initially in countries including Belgium, France, Germany, Italy, Sweden and Switzerland.

Nick Haggar, Head of Sandoz Western Europe, Middle East and Africa, said: “Sandoz is already a regional …

/by

Sandoz launches generic version of key anti-depressant Cipralex® in several European countries

Holzkirchen, June 4, 2014 – Sandoz, the generic pharmaceuticals division of Novartis, today announced the launch in several European countries of generic escitalopram, an affordable and high-quality version of reference product Cipralex®.

The Sandoz product, which is available in all strengths approved for the reference product (5mg, 10mg, 15mg and 20mg), was launched initially in countries including Belgium, France, Germany, Italy, Sweden and Switzerland.

Nick Haggar, Head of Sandoz Western Europe, Middle East and Africa, said: “Sandoz is already a regional …

/by

Sandoz launches AirFluSal® Forspiro® in South Korea

Seoul, May 14 2014 – Sandoz Korea announces that it is launching today AirFluSal® Forspiro®, an innovative new inhaler for patients with asthma and/or chronic obstructive pulmonary disease (COPD).

​The product was first approved in Denmark in December, 2013 with subsequent approvals in Germany, Belgium, Sweden, Norway, Hungary, Romania, Bulgaria and South Korea.

“We are pleased to launch AirFluSal® Forspiro® in South Korea. This is a milestone in our strategy of bringing our world class innovative inhaler to patients in Korea,” said Sujun Park, Country Head of …

/by

Court supports access to Sandoz’s innovative respiratory device in Norway

We are pleased that a court in Norway has denied GSK’s request to restrict access to Sandoz’s AirFluSal® Forspiro® in Norway. AirFluSal® Forspiro® provides patients with asthma and/or COPD with an award-winning innovative device for delivering the proven combination of salmeterol (a long-acting inhaled ß2-agonist) and fluticasone (an inhaled corticosteroid). We look forward to continuing to provide patients access to this important device. The decision is still subject to appeal.

About Sandoz

Sandoz, the generic pharmaceuticals division of Novartis, is a global …

/by

Sandoz recognizes World Asthma Day 2014

Today Sandoz recognizes World Asthma Day. World Asthma Day is an annual event organized by the Global Initiative for Asthma (GINA) with the goal of improving asthma awareness and care around the world. This year’s theme is, “It’s time to control asthma.”

A chronic, inflammatory lung disease, asthma is currently the most common non-communicable disease amongst children worldwide. GINA estimates that there are 300 million sufferers worldwide and there may be an additional 100 million people living with asthma by 2025.

Asthma is characterized by airway obstruction which results in …

/by